

EL668291634US EL668291634US
DATE DEPOSITED: 07/26/2001

MAIL DATE CANCELLED
JUL 3 0 2000

3

JUL 30 2009

DATE DEPOSITED: 07/26/2001

PTO/SB/21 (08-00)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number 09/774,940

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
respond to a collection of information unless it displays a valid OMB control number.

1

AUG 01 2001

RECEIVED

 <h1>TRANSMITTAL FORM</h1> <p><i>(to be used for all correspondence after initial filing)</i></p>		Application Number	09/774,940
		Filing Date	01/31/2001
		First Named Inventor	Mills, et al.
		Group Art Unit	1646
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission		Attorney Docket Number	5157.002

ENCLOSURES *(check all that apply)*


<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group		
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences		
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)		
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information		
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter		
<input checked="" type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):		
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer			
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund			
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____			
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application				
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53				
SEE REMARKS				
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="padding: 5px; width: 30%;">Remarks</td> <td style="padding: 5px; width: 70%; vertical-align: top;"> 1. Transmittal Form PTO/SB/21 (1 page); 2. Fee Transmittal for FY 2001 PTO/SB/17 (1 page); 3. Response To The Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure (4 pages); 4. Substitute Sequence Listing (1 page); 5. Copy of Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And Amino Acid Sequence Disclosures (2 pages); 6. Petition For Extension Of Time Under 37 CFR 1.126(e) (1 page); 7. A 3.5 inch, 1.44Mb disk containing computer readable form of Substitute Sequence Listing; 8. Post Card </td> </tr> </table>			Remarks	1. Transmittal Form PTO/SB/21 (1 page); 2. Fee Transmittal for FY 2001 PTO/SB/17 (1 page); 3. Response To The Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure (4 pages); 4. Substitute Sequence Listing (1 page); 5. Copy of Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And Amino Acid Sequence Disclosures (2 pages); 6. Petition For Extension Of Time Under 37 CFR 1.126(e) (1 page); 7. A 3.5 inch, 1.44Mb disk containing computer readable form of Substitute Sequence Listing; 8. Post Card
Remarks	1. Transmittal Form PTO/SB/21 (1 page); 2. Fee Transmittal for FY 2001 PTO/SB/17 (1 page); 3. Response To The Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure (4 pages); 4. Substitute Sequence Listing (1 page); 5. Copy of Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And Amino Acid Sequence Disclosures (2 pages); 6. Petition For Extension Of Time Under 37 CFR 1.126(e) (1 page); 7. A 3.5 inch, 1.44Mb disk containing computer readable form of Substitute Sequence Listing; 8. Post Card			

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Dunlap, Coddng & Rogers, P.C., 9400 North Broadway, Suite 420, Oklahoma City, OK 73114 Kathryn L. Hester, Ph.D., Reg. No. 46,768
Signature	
Date	7-26-01

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail or U.S. Express mail no. EL668291634US in an envelope addressed to the address below on this date: 07/26/2001

Typed or printed name	Kathryn L. Hester, Ph.D.		
Signature		Date	7-26-01

SEND TO: Box Patent Application
Commissioner For Patents
Washington, D.C. 20231



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/774,940	01/31/2001	Stanley L. Mills	5857.002

CONFIRMATION NO. 6337

FORMALITIES LETTER



OC00000006062439

Dunlap, Codding & Rogers, P.C.
9400 North Broadway, Suite 420
Oklahoma City, OK 73114

5155
Date Mailed: 05/10/2001
JUL 26 2001
TRADEMARK COPIES
* * * * *

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

DD

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE